Clinical Trial Update: Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating two doses of apremilast (CC-10004) in Japanese patients with moderate-to-severe plaque-type psoriasis; study completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Amgen | Conditions: Psoriasis, Psoriatic Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2020-03-20